摘要
目的回顾性分析以奥沙利铂为基础的FOLFOX-4方案与以多西他赛为基础的DF方案一线治疗晚期胃癌的临床疗效和毒副反应。方法收集中国人民解放军总医院55例晚期胃癌患者,一线应用FOLFOX-4方案26例,DF方案29例。所有患者至少接受3个周期FOLFOX-4方案或2个周期DF方案,且疗效可评价。结果 FOLFOX-4组客观有效率(ORR)为26.9%,疾病控制率(DCR)为73.1%,中位疾病无进展期(mPFS)为5.68月,中位总生存期(mOS)为13.89月。DF组ORR为20.7%,DCR为69.0%,mPFS为3.96月,mOS为12.71月。2组ORR、DCR、mPFS以及mOS比较差异均无统计学意义(均P>0.05)。2组毒副反应出现Ⅲ-Ⅳ级白细胞减少DF组为多,2组比较差异有统计学意义(P<0.05)。结论 FOLFOX-4和DF方案疗效相似,毒副作用可耐受,可以作为晚期胃癌的有效化疗方案选择。
Objective To retrospectively analyze the clinical efficacy and adverse effect of FOLFOX-4 regimen（oxaliplatin combined with fluorouracil and leucovorin） and DF regimen（docetaxel combined with fluorouracil） in the first-line treatment of advanced gastric cancer（AGC）.Methods Fifty-five patients with AGC were treated with at least 3 cycles of FOLFOX-4 regimen（n=26） or 2 cycles of DF regimen.Results The overall response rate（ORR）,disease control rate（DCR）,median progression-free survival（mPFS） and median overall survival（mOS） were,respectively,26.9%,73.1%,5.68 months and 13.89 months in FOLFOX-4 regimen treatment group,and 20.7%,69.0%,3.96 months and 12.71 months in DF regimen treatment group,without significant differences between the two groups（P〉0.05）.The incidence of grade Ⅲ-Ⅳ neutropenia in DF regimen treatment group was significantly higher than that in FOLFOX-4 regimen treatment group（P〈0.05）.Conclusion Both DF and FOLFOX-4 regimens are effective and tolerable in the treatment of AGC.
出处
《南昌大学学报（医学版）》
CAS
2012年第5期55-58,共4页
Journal of Nanchang University：Medical Sciences
关键词
晚期胃癌
一线化疗
奥沙利铂
多西他赛
advanced gastric cancer； first-line treatment； oxaliplatin； docetaxel；
